succinobucol has been researched along with Diabetes Mellitus, Type 2 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kourounakis, AP; Ladopoulou, E; Matralis, AN | 1 |
| Choi, J; Cooper, J; Klug, E; L'Allier, PL; Lewis, EF; McMurray, JJ; Pfeffer, MA; Schumi, J; Scott, R; Small, R; Tardif, JC | 1 |
1 trial(s) available for succinobucol and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial.
Topics: Acute Coronary Syndrome; Adult; Aged; Antioxidants; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Endpoint Determination; Female; Humans; Male; Middle Aged; Probucol | 2008 |
1 other study(ies) available for succinobucol and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
New multifunctional Di-tert-butylphenoloctahydro(pyrido/benz)oxazine derivatives with antioxidant, antihyperlipidemic, and antidiabetic action.
Topics: Animals; Antioxidants; Atherosclerosis; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Farnesyl-Diphosphate Farnesyltransferase; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Lipoproteins, LDL; Male; Mice; Oxidative Stress; Probucol; Rats | 2013 |